Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Part of paid clinical trials in San Francisco, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05162443
Status
Approved For Marketing

Conditions

  • Advanced Cancer
  • Malignant Neoplasm
  • Metastatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • adagrasib (MRTX849) — DRUG
    adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen

Study Details

The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.

Key Dates

Status verified
Aug 2025

Locations (11)

FacilityCityStateZIPSite coordinators
California Pacific Medical CenterSan FranciscoCalifornia94115-
Providence Medical Group Santa Rosa - Cancer CenterSanta RosaCalifornia95403-
Hartford HospitalHartfordConnecticut06106-
Piedmont Cancer InstituteAtlantaGeorgia30318-
Mayo Clinic - RochesterRochesterMinnesota55905-
Renown HealthRenoNevada89502-
Lehigh Valley Cancer InstituteAllentownPennsylvania18103-
Lumi ResearchKingwoodTexas77339-
Virginia Cancer InstituteRichmondVirginia23230-
Seattle Integrative Cancer CenterRentonWashington98057-
Swedish Cancer InstituteSeattleWashington98104-

Find similar trials in San Francisco, CA

By research site
California Pacific Medical Center· San Francisco, CAProvidence Medical Group Santa Rosa - Cancer Center· Santa Rosa, CAHartford Hospital· Hartford, CTPiedmont Cancer Institute· Atlanta, GAMayo Clinic - Rochester· Rochester, MNRenown Health· Reno, NV

Related Studies